Fol. Biol. 2016, 62, 235-240
https://doi.org/10.14712/fb2016062060235
The Relationship of Kynurenine and Neopterin Levels and Their Association with a Selection of Other Immune Markers in Chronic Myeloid Leukaemia Patients
References
1. 1993) Divergent in vivo and in vitro antileukemic activity of recombinant interferon β in patients with chronic-phase chronic myelogenous leukemia. Ann. Hematol. 67, 205-211.
< , W. E., Peschel, C., Despres, D., Aman, J., Trautman, P., Tilg, H., Rudolf, G., Huttmann, H., Obermeier, J., Herold, M., Huber, C. (https://doi.org/10.1007/BF01715048>
2. 2001) Aging and proinflammatory cytokines. Curr. Opin. Hematol. 8, 131-136.
< , H., Pedersen, M., Pedersen, B. K. (https://doi.org/10.1097/00062752-200105000-00001>
3. 2001) Human primary CD4+ T cells activated in the presence of IFN-α 2b express functional indoleamine 2,3-dioxygenase. J. Interferon Cytokine Res. 21, 431-437.
< , S., Romerio, F., Mirandola, P., Barion, P., Bemis, K., Zella, D. (https://doi.org/10.1089/107999001750277916>
4. 2011) Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr. Vasc. Pharmacol. 9, 188-199.
< , S., Cirillo, P., Pacileo, M., Petrillo, G., D’Ascoli, G. L., Maresca, F., Ziviello, F., Chiariello, M. (https://doi.org/10.2174/157016111794519372>
5. 2013) Redox regulation of the immune response. Redox Rep. 18, 88-94.
< , J. M., Becker, K., Fuchs, D., Sucher, R. (https://doi.org/10.1179/1351000213Y.0000000044>
6. 1999) Neopterin: a review. Exp. Dermatol. 8, 167-176.
< , F. F. (https://doi.org/10.1111/j.1600-0625.1999.tb00367.x>
7. 1982) Urinary neopterine in the assessment of lymphoid and myeloid neoplasia, and neopterine levels in haemolytic anaemia and benign monoclonal gammopathy. Clin. Biochem. 15, 34-37.
< , A., Fuchs, D., Grunewald, K., Huber, H., Konig, K., Wachter, H. (https://doi.org/10.1016/S0009-9120(82)90403-9>
8. 1997) High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant. 20, 365-368.
< , L., Korholz, D., Nussbaum, P., Bonig, H., Burdach, S., Zintl, F. (https://doi.org/10.1038/sj.bmt.1700902>
9. 2006) Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol (Praha) 52, 47-58.
, Z., Klamová, H., Janatková, I., Šandová, P., Šterzl, I., Sobotková, E., Hamšíková, E., Haškovec, C., Písačka, M., Cetkovský, P., Michalová, K., Faber, E., Heřmanová, Z., Ordeltová, M., Roubalová, K., Roth, Z., Vonka, V. (
10. 2010) Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin. Dev. Immunol. 2010, 137320.
< , Z., Klamova, H., Janatkova, I., Malickova, K., Kralikova, P., Sterzl, I., Roth, Z., Hamsikova, E., Vonka, V. (https://doi.org/10.1155/2010/137320>
11. 2010) Maintenance of cellular tetrahydrobiopterin homeostasis. BMB Rep. 43, 584-592.
< , H. L., Park, Y. S. (https://doi.org/10.5483/BMBRep.2010.43.9.584>
12. 2011) Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throughput HPLC. Talanta 85, 1466-1471.
< , L., Solichova, D., Melichar, B., Kasparova, M., Plisek, J., Sobotka, L., Solich, P. (https://doi.org/10.1016/j.talanta.2011.06.027>
13. 2001) Dehydroepiandrosterone, ageing and immune activation. Exp. Gerontol. 36, 1739-1747.
< , M., Murr, C., Jager, M., Fuchs, D. (https://doi.org/10.1016/S0531-5565(01)00122-X>
14. 2006) Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int. J. Gynecol. Cancer 16, 240-252.
< , B., Solichova, D., Freedman, R. S. (https://doi.org/10.1111/j.1525-1438.2006.00294.x>
15. 2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171, 1652-1655.
< , A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A., Iwashima, M., Munn, D. H. (https://doi.org/10.4049/jimmunol.171.4.1652>
16. 2002) Neopterin as a marker for immune system activation. Curr. Drug Metab. 3, 175-187.
< , C., Widner, B., Wirleitner, B., Fuchs, D. (https://doi.org/10.2174/1389200024605082>
17. 2013) Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int. J. Cancer 132, 591-604.
< , G., Lim, H. Y., Weigert, A., Haussler, A., Myrczek, T., Waldner, M., Labocha, S., Ferreiros, N., Geisslinger, G., Lotsch, J., Becker, C., Brune, B., Tegeder, I. (https://doi.org/10.1002/ijc.27706>
18. 2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 109, 2497-2502.
< , L., Larrieu, P., Stroobant, V., Colau, D., Dolusic, E., Frederick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., Van den Eynde, B. J. (https://doi.org/10.1073/pnas.1113873109>
19. 2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27, 3889-3900.
< , G. C. (https://doi.org/10.1038/onc.2008.35>
20. 1991) Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res. 51, 6250-6253.
, G., Krainer, M., Herold, M., Ludwig, H., Wachter, H., Huber, H. (
21. 2011) Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells. Transpl. Immunol. 25, 119-123.
< , S., Sucher, R., Kurz, K., Fuchs, D., Brandacher, G. (https://doi.org/10.1016/j.trim.2011.06.005>
22. 2010) Neopterin, a prognostic marker in human malignancies. Cancer Lett. 287, 13-22.
< , R., Schroecksnadel, K., Weiss, G., Margreiter, R., Fuchs, D., Brandacher, G. (https://doi.org/10.1016/j.canlet.2009.05.008>
23. 2005) Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin. Cancer Res. 11, 6247-6255.
< , M., Rakhit, A., Rittweger, K., O’Brien, S., Cortes, J., Fettner, S., Hooftman, L., Kantarjian, H. (https://doi.org/10.1158/1078-0432.CCR-05-0882>
24. 2015) Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol. 6, 34.
< , N., Van den Eynde, B. J. (https://doi.org/10.3389/fimmu.2015.00034>
25. 2015) Kynurenine and uric acid levels in chronic myeloid leukemia patients. Oncoimmunology 4, e992646.
< , V., Humlova, Z., Klamova, H., Kujovska-Krcmova, L., Petrackova, M., Hamsikova, E., Krmencikova-Fliegl, M., Duskova, M., Roth, Z. (https://doi.org/10.4161/2162402X.2014.992646>
26. 2015) Immunology of chronic myeloid leukemia: current concepts and future goals. Expert Rev. Clin. Immunol. 11, 511-522.
< , V., Petrackova, M. (https://doi.org/10.1586/1744666X.2015.1019474>
27. 2002) Neopterin production, tryptophan degradation, and mental depression – what is the link? Brain Behav. Immun. 16, 590-595.
< , B., Laich, A., Sperner-Unterweger, B., Ledochowski, M., Fuchs, D. (https://doi.org/10.1016/S0889-1591(02)00006-5>
28. 2012) Association between serum neopterin and inflammatory activation in chronic kidney disease. Mediators Inflamm. 2012, 476979.
< , A. K., Sharma, V., Jha, V. (https://doi.org/10.1155/2012/476979>
29. 2014) Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. Cancer 120, 3370-3377.
< , H., Tell, G. S., Vollset, S. E., Ueland, P. M., Nygard, O., Midttun, O., Meyer, K., Ulvik, A., Eussen, S. J. (https://doi.org/10.1002/cncr.28869>